PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats
Abstract
Background Peroxisome proliferator-activated receptor (PPAR)alpha is highly expressed in the heart. PPAR alpha may play a role in cardiac hypertrophy, but effects on cardiac function, inflammation, and fibrosis are unknown. We tested the hypothesis that the PPAR alpha activator fenofibrate prevents myocardial inflammation and fibrosis in angiotensin (Ang) II-infused rats. Methods and results Sprague Dawley rats received Ang II (120 ng/kg/min subcutaneously), fenofibrate (100 mg/kg/d p.o.), or Ang II + fenofibrate. After 7 d, systolic blood pressure (mmHg) was elevated (P < 0.01) in Ang II-infused rats (173 +/- 4) vs. controls (115 +/- 2) and reduced by fenofibrate (137 +/- 5). Electrophoretic mobility shift assay demonstrated that Ang II upregulated cardiac nuclear factor kappa B activity by 50%. Ang II significantly increased cardiac expression of vascular-cell adhesion molecule-1, platelet endothelial cell adhesion molecule, and intercellular adhesion molecule-1. Increases in expression of these inflammatory mediators were normalized by fenofibrate. Ang II-induced expression of transforming growth factor-beta 1, collagen deposition, and macrophage infiltration were partially prevented by fenofibrate. Conclusions The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats. The hypolipidemic drug fenofibrate may be useful in prevention and treatment of myocardial disease associated with hypertension and hyperlipidemia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Diep et al. and Goya et al. reported that FF increases endothelial Nitric Oxide (NO) availability.
“Diep et al. [101] and Goya et al. [102] reported that FF increases endothelial Nitric Oxide (NO) availability.”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [101]
Cites
Sahn, D. J., DeMaria, A. N., KISSLO, J. A., & Weyman, A. E. (1978) · Circulation · doi:10.1161/01.cir.58.6.1072 · Cited by 7,430 · see citing works
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217 · see citing works
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116 · see citing works
Weber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,035 · see citing works
Molecular Mechanisms of Myocardial Remodeling
Bernard Swynghedauw, A. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.215 · Cited by 1,448 · see citing works
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
Staels, B., Köenig, W., Habib, A., Merval, R., Lebret, M., Pineda‐Torra, I., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,134 · see citing works
Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7473 · Cited by 943 · see citing works
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · see citing works
Marx, N., Sukhova, G. K., Collins, T., Libby, P., & Plutzky, J. (1999) · Circulation · doi:10.1161/01.cir.99.24.3125 · Cited by 597 · see citing works
Gulick, T., Cresci, S., Caira, T., Moore, D. D., & Kelly, D. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11012 · Cited by 560 · see citing works
Poynter, M. E., & Daynes, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32833 · Cited by 551 · see citing works
Cardiac Actions of Angiotensin II: Role of an Intracardiac Renin-Angiotensin System
Baker, K. M., Booz, G. W., & Dostal, D. E. (1992) · Annual Review of Physiology · doi:10.1146/annurev.ph.54.030192.001303 · Cited by 508 · see citing works
Peroxisome proliterator-activated receptors, orphans with ligands and functions
Schoonjans, K., Martin, G. V., Staels, B., & Auwerx, J. H. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00006 · Cited by 488 · see citing works
Deactivation of peroxisome proliferator–activated receptor-α during cardiac hypertrophic growth
Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9056 · Cited by 465 · see citing works
Induction of Cardiac Fibrosis by Transforming Growth Factor-β1
Lijnen, P. J., Petrov, V. V., & Fagard, R. H. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3032 · Cited by 464 · see citing works
Brandt, J. M., Djouadi, F., & Kelly, D. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.23786 · Cited by 456 · see citing works
Nuclear factor kappa-B and the heart
Valen, G., Yan, Z.-Q., & Hansson, G. K. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01377-8 · Cited by 446 · see citing works
Diep, Q. N., Mabrouk, M. E., Cohn, J. S., Endemann, D., Amiri, F., Virdis, A., Neves, M. F., & Schiffrin, E. L. (2002) · Circulation · doi:10.1161/01.cir.0000016049.86468.23 · Cited by 345 · see citing works
Self-citationCampbell, F., Kozak, R., Wagner, A. M., Altarejos, J. Y., Dyck, J. R. B., Belke, D. D., Severson, D. L., Kelly, D. P., & Lopaschuk, G. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106054200 · Cited by 261 · see citing works
Angiotensin II Induces Cardiac Phenotypic Modulation and Remodeling In Vivo in Rats
Kim, S., Ohta, K., Hamaguchi, A., Yukimura, T., Miura, K., & Iwao, H. (1995) · Hypertension · doi:10.1161/01.hyp.25.6.1252 · Cited by 246 · see citing works
Characterization of angiotensin II receptor subtypes in rat heart.
Sechi, L. A., Griffin, C. A., Grady, E. F., Kalinyak, J. E., & Schambelan, M. (1992) · Circulation Research · doi:10.1161/01.res.71.6.1482 · Cited by 231 · see citing works
Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat.
Crawford, D. C., Chobanian, A. V., & Brecher, P. I. (1994) · Circulation Research · doi:10.1161/01.res.74.4.727 · Cited by 229 · see citing works
Wu, L., Iwai, M., Hironori Nakagami, A., Li, Z., Chen, R., Suzuki, J., Akishita, M., Marc De Gasparo, B., & Horiuchi, M. (2001) · Circulation · doi:10.1161/hc4601.099404 · Cited by 217 · see citing works
Ruiz‐Ortega, M., Lorenzo, Ó., Rupérez, M., Blanco, J., & Egido, J. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64130-2 · Cited by 176 · see citing works
Myocyte death in heart failure
Anversa, P., Kajstura, J., & Olivetti, G. (1996) · Current Opinion in Cardiology · doi:10.1097/00001573-199605000-00004 · Cited by 123 · see citing works
Cardiac aldosterone production and ventricular remodeling
Delcayre, C., Silvestre, J., Garnier, A., Oubénaı̈ssa, A., Cailmail, S., Tatara, E., Bernard Swynghedauw, A., & Robert, V. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00973.x · Cited by 123 · see citing works
Effects of Lipid-Lowering Agents in the Dahl Salt-Sensitive Rat
Wilson, T. W., Alonso‐Galicia, M., & Roman, R. J. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.225 · Cited by 108 · see citing works
Xu, X., Otsuki, M., Saito, H., Sumitani, S., Yamamoto, H., Asanuma, N., Kouhara, H., & Kasayama, S. (2001) · Endocrinology · doi:10.1210/endo.142.8.8340 · Cited by 82 · see citing works
Hypertrophic growth of cultured neonatal rat heart cells mediated by type 1 angiotensin II receptor
宮田, 節., & Haneda, T. (1994) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1994.266.6.h2443 · Cited by 74 · see citing works
Effect of AT1 receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension
Diep, Q. N., Mabrouk, M. E., Yue, P., & Schiffrin, E. L. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00984.2001 · Cited by 68 · see citing works
Self-citationAngiotensin II Increases Left Ventricular Mass Without Affecting Myosin Isoform mRNAs
Sušić, D., Núñez, E., Frohlich, E. D., & Prakash, O. (1996) · Hypertension · doi:10.1161/01.hyp.28.2.265 · Cited by 57 · see citing works
Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats.
Schiffrin, E. L., Thomé, F. S., & Genest, J. J. (1983) · Hypertension · doi:10.1161/01.hyp.5.6_pt_3.v16 · Cited by 49 · see citing works
Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease
Lorell, B. H. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00258-1 · Cited by 48 · see citing works
Kiarash, A., Pagano, P. J., Tayeh, M. A., Rhaleb, N., & Carretero, O. A. (2001) · Hypertension · doi:10.1161/01.hyp.37.1.58 · Cited by 34 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 643 · see citing works
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 551 · see citing works
Savoia, C., & Schiffrin, E. L. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mnh.0000203189.57513.76 · Cited by 286 · see citing works
Schiffrin, E. L., & Touyz, R. M. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00262.2004 · Cited by 249 · see citing works
Involvement of PPAR nuclear receptors in tissue injury and wound repair
Michalik, L. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27958 · Cited by 236 · see citing works
Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
Jasińska-Stroschein, M., Owczarek, J., & Orszulak–Michalak, D. (2007) · PubMed · Cited by 192 · see citing works
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Park, C. W., Zhang, Y., Zhang, X., Wu, J., Chen, L., Cha, D. R., Su, D., Hwang, M.-T., Fan, X., Davis, L., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000209 · Cited by 202 · see citing works
NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology
Manea, A. (2010) · Cell and Tissue Research · doi:10.1007/s00441-010-1060-y · Cited by 167 · see citing works
Zhang, J., Cheng, Y., Gu, J., Wang, S., Zhou, S., Wang, Y., Tan, Y., Feng, W., Fu, Y., Mellen, N. M., et al. (2016) · Clinical Science · doi:10.1042/cs20150623 · Cited by 158 · see citing works
Touyz, R. M., & Schiffrin, E. L. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.014 · Cited by 152 · see citing works
Shiroshita-Takeshita, A., Brundel, B. J. J. M., Burstein, B., Leung, T. K., Mitamura, H., Ogawa, S., & Nattel, S. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.01.002 · Cited by 147 · see citing works
PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes
Ding, G., Cheng, L., Qin, Q., Frontin, S., & Yang, Q. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.03.422 · Cited by 140 · see citing works
Hanna, I. R., Heeke, B., Bush, H., Brosius, L., King-Hageman, D., Dudley, S. C., Beshai, J. F., & Langberg, J. J. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.05.010 · Cited by 132 · see citing works
Robinson, E., & Grieve, D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.003 · Cited by 130 · see citing works
Cardiac hypertrophy is enhanced in PPAR -/- mice in response to chronic pressure overload
Smeets, P. J. H., Teunissen, B. E. J., Willemsen, P. H. M., van Nieuwenhoven, F. A., Brouns, A. E., Janssen, B. J., Cleutjens, J. P. M., Staels, B., Vusse, G. J., & van Bilsen, M. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn001 · Cited by 126 · see citing works
Li, Y., Qi, Y., Huang, T. H.-W., Yamahara, J., & Roufogalis, B. D. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00708.x · Cited by 113 · see citing works
Peroxisome proliferator-activated receptors and cardiovascular remodeling
Schiffrin, E. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00677.2004 · Cited by 110 · see citing works
Ichihara, S., Obata, K., Yamada, Y., Nagata, K., Noda, A., Ichihara, G., Yamada, A., Kato, T., Izawa, H., Murohara, T., et al. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.05.013 · Cited by 104 · see citing works
Teunissen, B. E. J., Smeets, P. J. H., Willemsen, P. H. M., Windt, L. J. D., Vandervusse, G. J., & VANBILSEN, M. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.04.026 · Cited by 105 · see citing works
Barbiero, J. K., Santiago, R. M., Tonin, F. S., Boschen, S. L., da Silva, L. M., Werner, M. F. D. P., Cunha, C. D., Lima, M. M. S., & Vital, M. A. B. F. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.02.009 · Cited by 97 · see citing works
PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation
Ren, Y., Sun, C., Sun, Y., Tan, H., Wu, Y., Cui, B., & Wu, Z. (2009) · Vascular Pharmacology · doi:10.1016/j.vph.2009.06.004 · Cited by 96 · see citing works
Besson, V. C., Chen, X. R., Plotkine, M., & Marchand‐Leroux, C. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.019 · Cited by 96 · see citing works
Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?☆
Balakumar, P., & Jagadeesh, G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.07.003 · Cited by 94 · see citing works
PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts
Chintalgattu, V., HARRIS, G., Akula, S. M., & Katwa, L. C. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.01.010 · Cited by 93 · see citing works
Wadosky, K. M., & Willis, M. S. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00703.2011 · Cited by 90 · see citing works
Schutta, M. H. (2007) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2007.06368.x · Cited by 89 · see citing works
Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators
Han, S. H., Quon, M. J., & Koh, K. K. (2005) · Hypertension · doi:10.1161/01.hyp.0000187900.36455.4c · Cited by 98 · see citing works
Balakumar, P., & Kathuria, S. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01938.x · Cited by 78 · see citing works
Walker, A. E., Kaplon, R. E., Lucking, S. M. S., Russell, M. J., Eckel, R. H., & Seals, D. R. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.203661 · Cited by 76 · see citing works
Chicco, A. J., Sparagna, G. C., McCune, S. A., Johnson, C. A., Murphy, R. C., Bolden, D. A., Rees, M. L., Gardner, R. T., & Moore, R. L. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.114264 · Cited by 73 · see citing works
Chen, R., Xue, J., & Xie, M.-L. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.05.015 · Cited by 71 · see citing works
McVicker, B. L., & Bennett, R. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00318 · Cited by 71 · see citing works
Du, X., Lu, F. Y., & Kiriazis, H. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.10.016 · Cited by 68 · see citing works
PPARs as therapeutic targets in cardiovascular disease
van Bilsen, M., & van Nieuwenhoven, F. A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.512917 · Cited by 68 · see citing works
Varkey, M., Ding, J., & Tredget, E. E. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.070 · Cited by 67 · see citing works
Wei, Y., Clark, S. E., Thyfault, J. P., Uptergrove, G. M., Li, W., Whaley‐Connell, A. T., Ferrario, C. M., Sowers, J. R., & Ibdah, J. A. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080697 · Cited by 66 · see citing works
Espira, L., & Czubryt, M. P. (2009) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-105 · Cited by 66 · see citing works
Duhaney, T.-A. S., Cui, L., Rude, M. K., LeBrasseur, N. K., Ngoy, S., Silva, D. S. D., Siwik, D. A., Liao, R., & Sam, F. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.086926 · Cited by 64 · see citing works
Interplay between statins and PPARs in improving cardiovascular outcomes: a double‐edged sword?
Balakumar, P., & Mahadevan, N. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01597.x · Cited by 63 · see citing works
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62 · see citing works
Azimzadeh, O., Sievert, W., Sarioglu, H., Yentrapalli, R., Barjaktarović, Ž., Sriharshan, A., Ueffing, M., Janik, D., Aichler, M., Atkinson, M. J., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr400071g · Cited by 62 · see citing works
Pellieux, C., Aasum, E., Larsen, T. S., Montessuit, C., Papageorgiou, I., Pedrazzini, T., & Lerch, R. A. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.004 · Cited by 61 · see citing works
Tikellis, C., Cooper, M. E., & Thomas, M. C. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.007 · Cited by 61 · see citing works
Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells
Li, Z., Ou-Yang, P.-H., & Han, X.-P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.09.018 · Cited by 60 · see citing works
Bansal, T., Chatterjee, E., Singh, J., Ray, A., Kundu, B., Thankamani, V., Sengupta, S., & Sarkar, S. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.788299 · Cited by 60 · see citing works
Anti-inflammatory role of fenofibrate in treating diseases
Jin, L., Hu, H., Ji, Y., Jia, Z., Peng, M., & Huang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2022.8534 · Cited by 58 · see citing works
Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 58 · see citing works
Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity
Ichihara, S., Yamada, Y., Kawai, Y., Osawa, T., Furuhashi, K., Duan, Z., & Ichihara, G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.027 · Cited by 58 · see citing works
Effects of Fenofibrate on Cardiac Remodeling in Aldosterone-Induced Hypertension
LeBrasseur, N. K., Duhaney, T.-A. S., Silva, D. S. D., Cui, L., Ip, P. C., Joseph, L., & Sam, F. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.092403 · Cited by 56 · see citing works
Subramanian, V., Seemann, I., Merl‐Pham, J., Hauck, S. M., Stewart, F., Atkinson, M. J., Tapio, S., & Azimzadeh, O. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00795 · Cited by 51 · see citing works
Goikoetxea, M. J., Beaumont, J., González, A., López, B., Querejeta, R., Larman, M., & Dı́ez, J. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.11.016 · Cited by 51 · see citing works
Fenofibrate Prevents the Development of Angiotensin II–Dependent Hypertension in Mice
Vera, T., Taylor, M., Bohman, Q. C., Flasch, A. K., Roman, R. J., & Stec, D. E. (2005) · Hypertension · doi:10.1161/01.hyp.0000153317.06072.2e · Cited by 50 · see citing works
Nam, J. S., Cho, M. H., Lee, G. T., Park, J. S., Ahn, C. W., Soo, B., Lim, S. K., Kim, K. R., Ha, H., & Lee, H. C. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.01.032 · Cited by 49 · see citing works
Peroxisome proliferator‐activated receptors and inflammation: take it to heart
Smeets, P. J. H., Planavila, A., Vusse, G. J., & van Bilsen, M. (2007) · Acta Physiologica · doi:10.1111/j.1748-1716.2007.01752.x · Cited by 49 · see citing works
Li, H., She, Z., Li, T., Wang, A., Yang, Q., Wei, Y.-S., Wang, Y., & Liu, D. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.085399 · Cited by 49 · see citing works
Targeting Apoptosis in the Heart of Streptozotocin-Induced Diabetic Rats
Baraka, A., & Abdel-Gawad, H. S. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409356557 · Cited by 47 · see citing works
Zhao, X., & Li, L. (2008) · American Journal of Nephrology · doi:10.1159/000116885 · Cited by 46 · see citing works
Role of the Peroxisome Proliferator Activated Receptors in Hypertension
Fang, S., Livergood, M. C., Nakagawa, P., Wu, J. F., & Sigmund, C. D. (2021) · Circulation Research · doi:10.1161/circresaha.120.318062 · Cited by 44 · see citing works
Ran, J., Hirano, T., & Adachi, M. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00199.2004 · Cited by 45 · see citing works
Cooper, M. E., Tikellis, C., & Thomas, M. C. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220408.91987.eb · Cited by 43 · see citing works
Linz, W., Wohlfart, P., Baader, M., Breitschopf, K., Falk, E., Schäfer, H., Gerl, M., Kramer, W., & Rütten, H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.58 · Cited by 44 · see citing works
Pleiotropic actions of fenofibrate on the heart
Balakumar, P., Rohilla, A., & Mahadevan, N. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.11.002 · Cited by 42 · see citing works
Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension
Gilbert, K., Nian, H., Yu, C., Luther, J. M., & Brown, N. J. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835e8227 · Cited by 41 · see citing works
Gilde, A. J., Fruchart, J., & Staels, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.097 · Cited by 41 · see citing works
Fenofibrate and metabolic syndrome
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · see citing works
Huang, T. H.-W., He, L., Qin, Q., Yang, Q., Peng, G., Harada, M., Qi, Y., YAMAHARA, J., Roufogalis, B. D., & Li, Y. J. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00750.x · Cited by 39 · see citing works
Barlaka, E., Galatou, E., Mellidis, K., Ravíngerová, T., & Lazou, A. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12166 · Cited by 37 · see citing works
Ji, Y., Liu, J., Liu, N., Wang, Z., & Liu, C.-H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.095 · Cited by 36 · see citing works
Transcriptomic analysis of PPARα-dependent alterations during cardiac hypertrophy
Smeets, P. J. H., den Bosch, H. D. V.-V., Willemsen, P. H. M., Stassen, A. P. M., Ayoubi, T., Vusse, G. J., & van Bilsen, M. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.90296.2008 · Cited by 36 · see citing works
Sekiguchi, K., Tian, Q., Ishiyama, M., Burchfield, J. S., Gao, F., Mann, D. L., & Barger, P. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01056.2006 · Cited by 36 · see citing works
Reduction of isoprenaline-induced myocardial TGF-β1 expression and fibrosis in osthole-treated mice
Chen, R., Xue, J., & Xie, M.-L. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.08.005 · Cited by 35 · see citing works
Yao, H., & Li, J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219816 · Cited by 34 · see citing works
Gao, S., Zhao, Z., Wu, R., Zeng, Y., Zhang, Z., Miao, J., & Yuan, Z. (2016) · Radiation and Environmental Biophysics · doi:10.1007/s00411-016-0675-0 · Cited by 33 · see citing works
Tordjman, K. M., Semenkovich, C. F., Coleman, T., Yudovich, R., Bak, S., Osher, E., Vechoropoulos, M., & Stern, N. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.094268 · Cited by 33 · see citing works
Althurwi, H. N., Elshenawy, O. H., & El‐Kadi, A. O. S. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000036 · Cited by 32 · see citing works
Ciuceis, C. D., Amiri, F., Iglarz, M., Cohn, J. S., Touyz, R. M., & Schiffrin, E. L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707215 · Cited by 32 · see citing works
Zhang, H., Pi, R., Li, R., Wang, P., Tang, F., Zhou, S., Gao, J., Jiang, J., Chen, S., & Liu, P. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.01.028 · Cited by 31 · see citing works
Cell-Based Mechanosensation, Epigenetics, and Non-Coding RNAs in Progression of Cardiac Fibrosis
Ferrari, S., & Pesce, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010028 · Cited by 30 · see citing works
Paw, M., Wnuk, D., Kądziołka, D., Sęk, A., Lasota, S., Czyż, J., Madeja, Z., & Michalik, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092571 · Cited by 30 · see citing works
Rose, M., Balakumar, P., & Singh, M. (2007) · Pharmacology · doi:10.1159/000103917 · Cited by 30 · see citing works
Jia, Z., Xue, R., Liu, G., Li, L., Yang, J., Pi, G., Ma, S., & Kan, Q. (2014) · PPAR Research · doi:10.1155/2014/541394 · Cited by 28 · see citing works
Cheng, H., Xi, Y., Chi, X., Wu, Y., & Liu, G.-Z. (2016) · Central European Journal of Immunology · doi:10.5114/ceji.2016.58817 · Cited by 28 · see citing works
Lockyer, P. P., Schisler, J. C., Patterson, C., & Willis, M. S. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0374 · Cited by 28 · see citing works
Kim, S.-J., Park, C., Lee, J. N., & Park, R. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.06.010 · Cited by 28 · see citing works
Kaur, J., Reddy, K., & Balakumar, P. (2010) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9086-7 · Cited by 27 · see citing works
The role of PPAR in myocardial response to ischemia in normal and diseased heart
Ravíngerová, T., Adameová, A., Čarnická, S., Nemčeková, M., Kelly, T., Matějíková, J., Galatou, E., Barlaka, E., & Lazou, A. (2011) · General Physiology and Biophysics · doi:10.4149/gpb_2011_04_329 · Cited by 27 · see citing works
Wang, G., Zhang, Q., Yuan, W., Wu, J., & Li, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126010 · Cited by 26 · see citing works
Diagnosis and Treatment of Myocardial Fibrosis in Hypertensive Heart Disease
Dı́ez, J. (2008) · Circulation Journal · doi:10.1253/circj.cj-07-1067 · Cited by 26 · see citing works
Wang, X., Zhu, X., Jiao, S., Qi, D., Yu, B., Xie, G., Liu, Y., Song, Y., Xu, Q., Xu, Q., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00743-z · Cited by 25 · see citing works
Wang, Y., Huang, X.-Y., Ma, Z., Wang, Y., Chen, X.-M., & Gao, Y. (2018) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2018.06.110 · Cited by 24 · see citing works
Effect of fenofibrate on LDL-induced endothelial dysfunction in rats
Yang, T., Chen, M., Luo, B., Yu, J., Jiang, J., & Li, Y. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0971-0 · Cited by 24 · see citing works
Wilson, J. L. L., Duan, R., Elmarakby, A. A., Alhashim, A., & Lee, D. L. (2012) · PPAR Research · doi:10.1155/2012/645969 · Cited by 23 · see citing works
Harding, P., & Murray, D. B. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.07.025 · Cited by 23 · see citing works
Abuissa, H. S., & O’Keefe, J. H. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00898.x · Cited by 23 · see citing works
Wang, W., Fang, Q., Zhang, Z., Wang, D. W., Wu, L., & Wang, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.528267 · Cited by 23 · see citing works
Sármán, B., Skoumal, R., Leskinen, H. K., Rysä, J., Ilves, M., Soini, Y., Tuukkanen, J., Pikkarainen, S., Lakó-Futó, Z., Sármán, B., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281e66653 · Cited by 23 · see citing works
Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System
Kuipers, I., van der Harst, P., Navis, G. J., van Genne, L., Morello, F., van Gilst, W. H., van Veldhuisen, D. J., & de Boer, R. A. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.108530 · Cited by 21 · see citing works
Ye, P., Li, J., Su, G., & Zhang, C. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.01.023 · Cited by 21 · see citing works
Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study
Huang, W., Yin, W., Chen, J. W., Jen, H.-L., Young, M. S., & Lin, S. J. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02176.x · Cited by 21 · see citing works
Peroxisome Proliferator-Activated Receptor ?? and Hypertensive Heart Disease
Goikoetxea, M. J., Beaumont, J., & ez, J. D. (2004) · Drugs · doi:10.2165/00003495-200464002-00003 · Cited by 21 · see citing works
- Authors
- Diep, Q.
- Affiliations
- Montreal Clinical Research Institute (CA)
- Corresponding author
- Diep, Q
- Venue
- Journal of Molecular and Cellular Cardiology
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 36
- Issue
- 2
- Pages
- 295-304
- ISSN
- 0022-2828 (ISSN-L)
- OpenAlex
- W2081813895
- Cited by
- 165
- References
- 34
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 7 · 2014: 6 · 2013: 7 · 2012: 7
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Molecular and Cellular Cardiology (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (acceptedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- fenofibrate, PPARα, angiotensin II, myocarditis, myocardial fibrosis, hypertension, NF-κB, adhesion molecules, TGF-β1, collagen deposition, macrophage infiltration, hyperlipidemia, cardioprotection
- MeSH terms
- Angiotensin II, Animals, Blood Pressure, Collagen, Electrocardiography, Fibrosis, Heart, Hypertension, Inflammation, Infusions, Intravenous, Myocardium, Fenofibrate, Transcription Factors, Transforming Growth Factor beta, NF-kappa B, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Intercellular Adhesion Molecule-1, Rats, Transforming Growth Factor beta1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
